share_log

Private Companies Are Micro-Tech (Nanjing) Co.,Ltd's (SHSE:688029) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.1b

Private Companies Are Micro-Tech (Nanjing) Co.,Ltd's (SHSE:688029) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.1b

私營公司是南微醫學(南京)股份有限公司(SHSE:688029)最大的股東,在市值下降11億元人民幣後遭受重創。
Simply Wall St ·  2024/11/19 14:28

Key Insights

主要見解

  • Micro-Tech (Nanjing)Ltd's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • The top 4 shareholders own 52% of the company
  • 21% of Micro-Tech (Nanjing)Ltd is held by Institutions
  • 南微醫學(南京)有限公司的顯著股權由私營公司持有,這表明關鍵決策受到了較大公衆股東的影響。
  • 前4大股東擁有該公司的52%。
  • 21%的南微醫學(南京)有限公司的股份由機構持有。

Every investor in Micro-Tech (Nanjing) Co.,Ltd (SHSE:688029) should be aware of the most powerful shareholder groups. We can see that private companies own the lion's share in the company with 25% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

每一位投資者在南微醫學(南京)有限公司(SHSE:688029)應當了解最強大的股東群體。我們可以看到,私營公司在該公司擁有25%的股份,也就是說,該團體在投資該公司中獲得的收益最大(或損失最大)。

As a result, private companies as a group endured the highest losses last week after market cap fell by CN¥1.1b.

因此,上週私營企業整體承受了最高的損失,因爲市值減少了11億人民幣。

Let's delve deeper into each type of owner of Micro-Tech (Nanjing)Ltd, beginning with the chart below.

讓我們從下面的圖表深入了解南微醫學(南京)有限公司的每種類型的所有者。

big
SHSE:688029 Ownership Breakdown November 19th 2024
SHSE:688029 所有權結構 2024年11月19日

What Does The Institutional Ownership Tell Us About Micro-Tech (Nanjing)Ltd?

機構所有權告訴我們關於南微醫學(南京)有限公司什麼?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

Micro-Tech (Nanjing)Ltd already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Micro-Tech (Nanjing)Ltd's historic earnings and revenue below, but keep in mind there's always more to the story.

南微醫學(南京)有限公司已經在股份登記上有機構投資者。實際上,他們在公司的股份相當可觀。這表明在專業投資者中具有一定的可信度。但我們不能僅僅依賴這一事實,因爲機構有時也會做出不好的投資,就像每個人一樣。當多個機構持有一隻股票時,總是存在『擁擠交易』的風險。當這樣的交易出現問題時,多個方可能會競相快速出售股票。在沒有增長曆史的公司中,這種風險會更高。您可以在下面看到南微醫學(南京)有限公司的歷史收益和營業收入,但請記住,故事遠不止於此。

big
SHSE:688029 Earnings and Revenue Growth November 19th 2024
上海證券交易所:688029 2024年11月19日的盈利和營業收入增長

We note that hedge funds don't have a meaningful investment in Micro-Tech (Nanjing)Ltd. China Science & Merchants Investment Management Group Co., Ltd. is currently the company's largest shareholder with 22% of shares outstanding. Nanjing New Weichuang Enterprise Management Consulting Co., Ltd. is the second largest shareholder owning 20% of common stock, and National Council for Social Security Fund holds about 5.5% of the company stock. Additionally, the company's CEO Derong Leng directly holds 1.3% of the total shares outstanding.

我們注意到對南微醫學(南京)有限公司的對沖基金投資並不顯著。中國科學與商貿投資管理集團有限公司目前是該公司的最大股東,持有22%的流通股份。南京新維創企業管理諮詢有限公司是第二大股東,持有20%的普通股,國家社會保障基金理事會持有大約5.5%的公司股票。此外,公司的CEO雷榮直接持有總流通股份的1.3%。

To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

爲了使我們的研究更有趣,我們發現前四名股東控制了公司一半以上的股份,這意味着該集團對公司的決策具有相當大的影響力。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

儘管研究公司的機構持股可以增加您的研究價值,但研究分析師的建議也是一個好習慣,以更深入地了解股票的預期表現。有相當數量的分析師關注該股,因此了解他們對未來的總體觀點可能很有用。

Insider Ownership Of Micro-Tech (Nanjing)Ltd

南微醫學(南京)有限公司的內部持股

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

雖然內部人員的精確定義可能具有主觀性,但幾乎所有人都認爲董事會成員是內部人員。管理層最終向董事會負責。然而,如果經理是創始人或CEO,那麼他們成爲執行董事會成員並不罕見。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。

Our most recent data indicates that insiders own some shares in Micro-Tech (Nanjing) Co.,Ltd. This is a big company, so it is good to see this level of alignment. Insiders own CN¥400m worth of shares (at current prices). It is good to see this level of investment by insiders. You can check here to see if those insiders have been buying recently.

我們最近的數據表明,內部人士擁有南微醫學(南京)有限公司的部分股份。 這是一家大公司,因此看到這樣的對齊水平是很好的。內部人士擁有價值40000萬人民幣的股份(按當前價格計算)。看到內部人士的這種投資水平是很好的。您可以在這裏查看這些內部人士是否最近有買入。

General Public Ownership

一般大衆所有權

With a 24% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Micro-Tech (Nanjing)Ltd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

公衆持有24%的股份,主要是由個人投資者組成,對南微醫學(南京)有限公司有一定的影響力。儘管這個股份規模相當可觀,但如果決策與其他大股東不同,這可能不足以改變公司政策。

Private Equity Ownership

股權投資公司持有8.8%的股份,有能力參與塑造以價值創造爲重點的公司策略。一些投資者可能會因此而受到鼓舞,因爲股權投資公司有時可以鼓勵市場看到公司的價值,從而採取有益的策略。另外,那些持有者可能在將其上市後退出投資。

With an ownership of 22%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

私人股權公司持有22%的所有權,可以在價值創造方面發揮塑造企業戰略的作用。 有些投資者可能會因此感到鼓舞,因爲私募股權有時能夠鼓勵幫助市場看到公司的價值的策略。 或者,這些持有人在把它上市後就退出了投資。

Private Company Ownership

私有公司的所有權

We can see that Private Companies own 25%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我們可以看到,私有公司擁有公司已發行的25%股份。僅從這個事實很難得出結論,因此有必要查看誰擁有這些私有公司。有時候內部人員或其他相關方會通過單獨的私人公司持有以公開公司的股份的權益。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Micro-Tech (Nanjing)Ltd , and understanding them should be part of your investment process.

我發現研究誰真正擁有一家公司非常有趣。但是要真正獲得洞察,我們還需要考慮其他信息。 舉個例子,投資風險這個無處不在的幽靈。 我們已經識別出南微醫學(南京)有限公司的一個警告信號,理解這些信號應該是您投資過程的一部分。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果您像我一樣,可能希望考慮這家公司是否會增長或縮小。幸運的是,您可以查看此免費報告,顯示分析師對其未來的預測。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論